Entera Bio Ltd. (ENTX)
| Market Cap | 61.04M -39.5% |
| Revenue (ttm) | n/a -76.8% |
| Net Income | -12.38M |
| EPS | -0.26 |
| Shares Out | 49.23M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,731 |
| Open | 1.240 |
| Previous Close | 1.240 |
| Day's Range | 1.224 - 1.255 |
| 52-Week Range | 0.910 - 3.220 |
| Beta | 1.55 |
| Analysts | Strong Buy |
| Price Target | 9.00 (+625.81%) |
| Earnings Date | May 8, 2026 |
About ENTX
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist pept... [Read more]
Financial Performance
In 2025, Entera Bio's revenue was $42,000, a decrease of -76.80% compared to the previous year's $181,000. Losses were -$11.44 million, 19.9% more than in 2024.
Financial StatementsAnalyst Summary
According to one analyst, the rating for ENTX stock is "Strong Buy" and the 12-month stock price target is $9.0.
News
Entera Bio Proxy statement: Proxy filing
Entera Bio filed a proxy statement on May 14, 2026, providing details for shareholder voting and corporate governance matters.
Entera Bio files to sell 19.57M ordinary shares for holders
16:22 EDT Entera Bio (ENTX) files to sell 19.57M ordinary shares for holders
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – Phase 3 protocol submitted with FDA feedback expected imminently; incremental data submitted ...
Entera Bio Registration statement: Registration filing
Entera Bio filed a registration statement on May 8, 2026, providing details about a securities offering with the SEC.
Entera Bio Quarterly report: Q1 2026
Entera Bio has published its Q1 2026 quarterly earnings report on May 8, 2026.
Entera Bio Earnings release: Q1 2026
Entera Bio released its Q1 2026 earnings on May 8, 2026, summarizing the period's financial results.
Entera Bio price target lowered to $9 from $10 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Entera Bio (ENTX) to $9 from $10 and keeps a Buy rating on the shares.
BriefCast Publishes Transcript: Entera Bio's Osteoporosis KOL Roundtable on EB613 - Oral Anabolic Tablet Opportunity
In a virtual Key Opinion Leader (KOL) roundtable hosted today, Entera Bio (Nasdaq: ENTX) convened globally recognized authorities in osteoporosis and women's health to discuss the current osteoporosis...
Entera Bio Transcript: KOL event
Experts highlighted a major treatment gap in osteoporosis due to injectable anabolic barriers, with strong demand for an oral option. EB613's phase II data show efficacy comparable to injectables, and its oral format could shift the treatment paradigm and improve patient access.
Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613
TEL AVIV, Israel, April 14, 2026 (GLOBE NEWSWIRE) -- TEL AVIV, Israel, April 14, 2026 -- Entera Bio Ltd. (Nasdaq: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today...
Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners
MIAMI, April 6, 2026 /PRNewswire/ -- Global law firm Greenberg Traurig, P.A. advised Israel-based Entera Bio Ltd.
Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds
TEL AVIV, Israel, April 02, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that it has entered into ...
Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates
EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – FDA Type A endpoint alignment in July 2025, Phase 3 protocol submitted to the FDA with commen...
Entera Bio Annual report: Q4 2025
Entera Bio has published its Q4 2025 annual report on March 27, 2026.
Entera Bio Earnings release: Q4 2025
Entera Bio released its Q4 2025 earnings on March 27, 2026, summarizing the period's financial results.
Entera Bio Slides: Corporate presentation
Entera Bio has posted slides in relation to its latest quarterly earnings report, which was published on March 11, 2026.
Entera Bio submits streamlined Phase 3 protocol to U.S. FDA for EB613
Entera Bio (ENTX) announced the submission to the U.S. Food and Drug Administration of a clinical amendment providing a streamlined Phase 3 protocol, statistical analysis plan, and open-label extensio...
Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis
Phase 3 study designed with total hip BMD primary endpoint assessed at 12 months, rather than at 24 months EB613 single tablet final commercial formulation (Next-Gen EB613) replaces multi-tablet EB613...
Entera Bio announces open market purchases of stock by board members
Entera Bio (ENTX) announced that several members of its Board of Directors, including the Company’s Chairman, have made open market purchases of the Company’s ordinary shares. These transactions follo...
Entera Bio Announces Open Market Purchases of Company Stock by Board Members
TEL AVIV, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, today announced t...
Entera Bio appoints Geno Germano as chairman of the board
Entera Bio (ENTX) announced that its Board of Directors has appointed Geno Germano as Chairman of the Board, effective February 4, 2026. Mr. Germano succeeds Gerald Lieberman, who is stepping…
Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones
New Chairman Joins Entera's Board with Senior Global Leadership Experience from Pfizer, Wyeth and Other Leading Biopharma Companies as Entera Advances Multiple Oral Peptide Programs Toward Significant...
Opko Health Entera Bio, Entera Bio expand partnership to advance PTH tablet
OPKO Health (OPK), through its wholly owned subsidiary, OPKO Biologics, and Entera Bio (ENTX), announced the expansion of their 2025 Collaboration and License Agreement to advance the first oral long-...
Entera Bio announces expected milestones for Q1 in 2026
Entera Bio (ENTX) announced its expected corporate milestones for the first quarter of 2026. Building on Entera’s July 29th 2025 alignment with FDA and FDA’s December 19th 2025 broad qualification…
Entera Bio ‘congratulates’ FNIH-ASBMR-SABRE team on FDA endpoint qualification
Entera Bio (ENTX) congratulates the FNIH-ASBMR-SABRE team following the Food and Drug Administration broad qualification of total hip bone mineral density as a validated regulatory endpoint for novel ...